{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:58Z","timestamp":1791924238688,"version":"4.3.4"},"reference-count":140,"publisher":"Baishideng Publishing Group Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJCO"],"published-print":{"date-parts":[[2020,4,24]]},"DOI":"10.5306\/wjco.v11.i4.190","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T05:51:19Z","timestamp":1587534679000},"page":"190-204","source":"Crossref","is-referenced-by-count":138,"title":["Nephrotoxicity in cancer treatment: An overview"],"prefix":"10.5306","volume":"11","author":[{"given":"Maria Lu\u00edsa Cordeiro","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno Bittencourt de","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe Ant\u00f4nio Fran\u00e7a da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anelise Costa dos Santos","family":"Botelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabr\u00edcio Freire de","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1613984"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02780312"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.30"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.50"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1254-8"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0508-2"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.04.007"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.21871"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4314\/ejhs.v28i6.5"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2016.02.064"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.nephro.2018.02.008"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.03.009"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.7.945"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850101)55:1<44::aid-cncr2820550107>3.0.co;2-b"},{"key":"ref15","unstructured":"Narins RG, Carley M, Bloom EJ, Harrison DS. The nephrotoxicity of chemotherapeutic agents. Semin Nephrol 1990; 10: 556-564"},{"key":"ref16","unstructured":"Graham ML, Janecek JL, Kittredge JA, Hering BJ, Schuurman HJ. The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources. Comp Med 2011; 61: 356-360"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw338"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1078155209352821"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.7.4338"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.9.923"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213504976"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.10.041"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.897701"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-694"},{"key":"ref25","unstructured":"Howell SB, Carmody J. Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults. Cancer Treat Rep 1977; 61: 1389-1391"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.15171\/jnp.2017.07"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1385\/MO:23:3:419"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2010.501930"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.5414\/cnp71130"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199346040-00006"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2010.02.003"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17278"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(71)90244-0"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12196"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.408"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(97)90042-1"},{"key":"ref37","unstructured":"Cordonnier D, Vert-Pr\u00e9 FC, Bayle F, Alix JL, Couderc P. [Nephrotoxicity of mitomycin C (apropos of 25 case reports). Results of a multicenter survey organized by the Society of Nephrology]. Nephrologie 1985; 6: 19-26"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(85)80035-4"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820501)49:9<1784::aid-cncr2820490909>3.0.co;2-6"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0319"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3091"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(95)90010-1"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.257"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(86)80112-3"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)80022-E"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh826"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.015"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2015.1013419"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1169-4"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(83)80060-2"},{"key":"ref51","unstructured":"Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS 3rd. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000; 28: 423-433"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.18926\/AMO\/32861"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.12.3062"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04395_2.x"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04875.x"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06698.x"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25139"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0070"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802023707"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq482"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538835"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214568581"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv222"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.176"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.01.210"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2016.06.002"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24662"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.2174\/1389557516666160321114917"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.09.017"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.09.001"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.064"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.3661"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-014-0135-0"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.06.027"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji242"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70108-0"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1131-5"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00600"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.08.159"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2013.039"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp058197"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Albanell J, Baselga J. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc) 1999; 35: 931-946","DOI":"10.1358\/dot.1999.35.12.564040"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2825"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000408"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy026"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0055"},{"key":"ref88","unstructured":"Ladanyi M, Cavalchire G, Morris SW, Downing J, Filippa DA. Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t(2;5) translocation in Hodgkin's disease. Am J Pathol 1994; 145: 1296-1300"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)90061-6"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2002.01534.x"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1038\/nature07399"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.12.013"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000321"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000326"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0379-y"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149873"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1713"},{"key":"ref100","unstructured":"Temsirolimus 2012, In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012\u20132013 Dec 10"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt233"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/0168-9525(93)90209-z"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.001"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.3109\/08860220903391226"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09936-x"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq715"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000079140"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051140"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1038\/nrc909"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv136"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283161012"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.07.014"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080455"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm311"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.8201"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080455"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.11.025"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn625"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm199"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00465-9"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0210-1"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.555"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.005"},{"key":"#cr-split#-ref128.1","unstructured":"Food and Drug Administration. Pembrolizumab (KEYTRUDA), checkpoint inhibitor. [published 2016 October 25 Oct"},{"key":"#cr-split#-ref128.2","unstructured":"cited 2019 December 16]. Available from: URL: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-checkpoint-inhibitor"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0478-8"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.02.057"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16603"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07311009"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.06.012"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200207000-00008"},{"key":"ref137","unstructured":"Webb DE, Austin HA 3rd, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 1988; 30: 141-145"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1382472"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3382-9"}],"container-title":["World Journal of Clinical Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v11\/i4\/190.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T02:29:31Z","timestamp":1696040971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v11\/i4\/190.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":140,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,24]]}},"URL":"https:\/\/doi.org\/10.5306\/wjco.v11.i4.190","relation":{},"ISSN":["2218-4333"],"issn-type":[{"value":"2218-4333","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,24]]}}}